Fundraising Fox

Orthobond

Monmouth Junction, US · Delaware corporation

orthobond.com

Orthobond develops proprietary antimicrobial nanosurface technology that covalently binds to metallic and polymeric surfaces to mechanically kill bacteria, viruses, and fungi without antibiotics or eluting chemicals. Its first products, including Ostaguard, are antimicrobial surface treatments for implantable medical devices, with intended future applications in textiles, consumer goods, and high-touch public surfaces.

HealthtechMedical DevicesNew Materialsin /orthobond-corporation

Founders & leadership

DN
David NicholsCEO
PG
Peter GoodwinDirector
FC
Frank CammisaDirector
KB
Khalil BarrageDirector
LD
Lisa D'UrsoDirector
DH
David HelfetDirector
PK
Peter K. ScaturroDirector
GL
Gregory LutzDirector
PV
Paul VolovichExecutive Officer

Competitors · 5

by search overlap

Companies competing with Orthobond for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
$1.1MraisedSep 2022 · 8 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NicholsExecutive Officer, Director
  • Peter GoodwinDirector
  • Frank CammisaDirector
  • Khalil BarrageDirector
  • Lisa D'UrsoDirector
  • David HelfetDirector
  • Peter K. ScaturroDirector
  • Gregory LutzDirector
  • Paul VolovichExecutive Officer
Offering amount
$15M
Amount sold
$1.1M
Minimum investment
$50K
Sales commissions
$750K
Placement agents
Kola Agbaje
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$146.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.